吉西他滨联合顺铂治疗复发性晚期头颈部癌的临床研究

 目的 评价吉西他滨联合顺铂治疗复发性晚期头颈部肿瘤的疗效及毒副作用。方法 对复治的晚期头颈部肿瘤患者，给予GEM 1000mg／m²静滴，第1、8d，每周期CDDP 60mg／m²，静滴（分5次第1-5d），21d为1周期，2周期后评定疗效，平均3．52个周期。结果 27例可评价疗效，完全缓解1例，部分缓解7例，总有效率29．63％，中位缓解期4．4个月，中位生存期9个月。毒副作用主要为剂量限制性毒性，表现为骨髓抑制。结论 吉西他滨加顺铂可作为复发性晚期头颈部肿瘤的挽救性化疗方案。

Clinical Study on Gemcitabine Combination with Cisplatin Therapy for Recurrent Advanced Head and Neck Cancer

Objective To evaluate the efficacy and toxicity of Gemcitabine (GEM) combination with cisplatin (CDDP) treatment in the recurrent advanced head and neck cancer. Methods Twenty-seven patients of recurrent advanced head and neck cancer were treated. The treatment schedule was consisting of GEM 1 000mg/ m 2iv, dl, d8 and CDDP 60mg/ m 2/cycle iv (divided into dl~5). Cycles repeated for 21 days. All patients received over 2 cycles of chemotherapy, median 3.52 cycles. Results The overall response rate was 29.63% (1 complete response and 7 partial response were observed in 27 patients). The median response duration was 4.4 months. The median survival period was 9 months. The dose-limiting toxicity was mainly hematologic. Neutropenia was the most frequent side-effect ( 85.18% of patients; grade 3~4 in 22.22%). Conclusion The GEM and CDDP combination has a palliative role in patients with recurrent advanced head and neck cancer.